Immunoprotection Provided by Salivary and Intestinal Protein-Based Antigens Against the Ixodid Tick

is among the most dangerous ticks in South America, as it is the species most associated with humans and is the main vector of . In the face of the problems related to tick control based on chemical acaricides, vaccines emerge as a promising method. In previous works, three salivary recombinant proteins (rAs8.9kDa, rAsKunitz, and rAsBasicTail) and one protein based on intestinal immunogenic regions (rAsChimera) were described with 59 to 92% vaccine efficacy against females. Here, we evaluate novel vaccine formulations containing binary or multiple combinations of the antigens rAs8.9kDa, rAsKunitz, rAsBasicTail, and rAsChimera against the three instars of the tick. A control group of mice was immunized with adjuvant alone (aluminum hydroxide gel) and compared to five groups immunized with formulations containing two, three, or four of the antigens. The formulations were safe, with no significant alterations to host behavior and hematological or biochemical parameters. Immunizations induced a significant increase in the CD19 B lymphocyte percentage in all groups, but no difference was seen for CD8 and CD4 T lymphocytes or CD14 monocytes. The best protection was observed for the formulations containing two antigens, which reached above 98% efficacy, while the groups containing three or four antigens presented 92.7 and 94.4% efficacy, respectively. All antigen combinations were promising as vaccine formulations against . The formulation containing rAs8.9kDa and rAsChimera showed the best efficacy and should be focused on in further experiments.